Pancreatic cancer – Keep reading Earl Groce’s success with CPI-613
No sign of cancer! Groce has been a part of a clinical trial since his diagnosis four-plus years ago and the results have been tremendous
Non-Small Cell Lung Cancer, NSCLC, patients with RET+ tumors – meet Pralsetinib
Background The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and
Triple Negative Breast Cancer patients – Capivasertib helps you survive
PURPOSE OF THE STUDY The trial was designed to evaluate the safety and efficacy of adding Capivasertib to Taxol as first-line therapy for metastatic TNBC
Recurrent Metastatic Head and Neck Squamous Cell Carcinoma and Salivary Gland Cancer – Two approved drugs demonstrated promising efficacy
Background This phase II trial was designed to evaluate the benefit of Keytruda® plus Zolinza® for recurrent Head and Neck Squamous Cell Carcinoma, HNSCC and
Tremelimumab in Advanced Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Background Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. Tremelimumab is an
Metastatic colorectal cancer – Tumor location, left or right, impacts efficacy in KRAS/RAS wild-type patients
Background Metastatic colorectal cancer, mCRC, is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumors driving varying prognosis. Patients
HER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201
When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium,
Combination of Two FDA Approved Drugs Shows Promise in BRAF V600E‒Mutated Glioma
In short The results of a phase II trial in patients with BRAF V600E mutations in high- and low-grade glioma, were reported at the 24th
Potential Cure of recurrent GBM with the Oncolytic Herpes Virus G47∆
Interim results The virus has been designated a breakthrough therapy in Japan. An interim analysis of a trial of the oncolytic herpes virus G47∆ has
Glioblastoma Moltiforme, GBM – NEW immunotherapies stop from growing in newly diagnosed patients
Background According to interim findings of a phase II trial, the combination of INO-5401, a T-cell–activating immunotherapy and INO-9012, an immune activator of a different
New anti-cancer drug, Tucatinib, reduces risk of death in metastatic HER2+ breast cancer
Background There is significant unmet medical need following treatment with Herceptin, Perjeta and Kadcyla in patients with metastatic HER2-positive breast cancer. In the HER2CLIMB trial,
Approved immunotherapy has shown a positive survival benefit in HER2+ breast cancer
This time, we’ll start from the end… Results of the study First of all, it is important to note that the research goals were not
